Flag of the European Union EU Clinical Trials Register Help

Clinical trials for japanese encephalitis vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: japanese encephalitis vaccine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-004366-34 Sponsor Protocol Number: 311_FU2013 Start Date*: 2013-12-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: Neutralizing Antibody Titers 6 Years after the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection
    Medical condition: Study population: adult volunteers who received a booster dose of JE-VC in prestudy IC51-311, no specific medical condition is investigated, only antibody check.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015595-10 Sponsor Protocol Number: IC51-322 Start Date*: 2010-03-23
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015588-15 Sponsor Protocol Number: IC51-323 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022265-10 Sponsor Protocol Number: IC51-325 Start Date*: 2011-12-28
    Sponsor Name:Intercell AG
    Full Title: LONG TERM IMMUNITY AND SAFETY WITH OR WITHOUT A BOOSTER DOSE FOLLOWING PRIMARY VACCINATION WITH THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION IN A JEV-ENDEMIC COUNTRY. ...
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018630-52 Sponsor Protocol Number: IC51-315 Start Date*: 2010-05-27
    Sponsor Name:Intercell AG
    Full Title: AN OPEN-LABEL, UNCONTROLLED PHASE 4 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS (JE) VACCINE IXIARO® (IC51) IN AN ELDERLY POPULATION
    Medical condition: IXIARO® is used to protect adults against Japanese encephalitis (JE). JE can be fatal or lead to long-term disability. Vaccination with Ixiaro should be considered for people who are at risk of exp...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10014596 Encephalitis Japanese B LLT
    12.1 10023119 Japanese B encephalitis LLT
    12.1 10023120 Japanese B viral encephalitis LLT
    12.1 10023122 Japanese B virus encephalitis LLT
    12.1 10023123 Japanese encephalitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022266-27 Sponsor Protocol Number: IC51-324 Start Date*: 2010-12-13
    Sponsor Name:Valneva Austria GmbH
    Full Title: Long term immunity and safety following vaccination with the Japanese Encephalitis vaccine IC51 (IXIARO®, JESPECT®) in a pediatric population in non-endemic countries. Uncontrolled, Phase 3 Follow-...
    Medical condition: JE can be fatal or lead to long-term disability. Vaccination should therefore be considered for people who are at risk of exposure to JEV by travelling to endemic regions. The study within which no...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    17.0 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    17.0 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    17.0 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    17.0 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004634-24 Sponsor Protocol Number: IC51-314 Start Date*: 2008-09-18
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY OF A COMMERCIAL BATCH OF THE JAPANESE ENCEPHALITIS VACCINE IC51 UP TO TWENTY-FOUR MONTHS POST FILLING, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014596 Encephalitis Japanese B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023300-27 Sponsor Protocol Number: JE-Boost Start Date*: 2010-12-09
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Ability of the new Vero-cell-derived inactivated Japanese encephalitis vaccine (IXIARO) to elicit a booster response in travellers previously vaccinated with traditional mouse-brain derived vaccine...
    Medical condition: The study subjects are healthy travelers and have no major chronic illnesses.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005173-23 Sponsor Protocol Number: V49_23 Start Date*: 2012-03-08
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH
    Full Title: A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Differ...
    Medical condition: Safety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to health...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10037742 Rabies PT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10037743 Rabies viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020450-33 Sponsor Protocol Number: IX-senesc2.0 Start Date*: 2010-06-23
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO®
    Medical condition: The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 65 years of age in comp...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10069544 Japanese encephalitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000100-14 Sponsor Protocol Number: IC51- 302 Start Date*: 2005-09-08
    Sponsor Name:Intercell AG
    Full Title: Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV). Double blind, randomized, placebo controlled phase 3 study
    Medical condition: Japanese encephalitis (JE) is the most common viral encephalitis, with over 50,000 cases reported annually. It is a considerable public health problem for many Asian countries (WHO 1997). Close to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005193-38 Sponsor Protocol Number: JEC01 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
    Medical condition: Japanese Encephalitis
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002474-36 Sponsor Protocol Number: IC51-301 Start Date*: 2005-04-20
    Sponsor Name:Intercell AG
    Full Title: Observer blinded, randomized Phase III study to investigate the non-inferiority of IC51 (JE-PIV) vs. JE-VAX as vaccines for japanese encephalitis in healthy volunteers
    Medical condition: Japanese encephalitis (JE) is the most common viral encephalitis, with over 50,000 cases reported annually. It is a considerable public health problem for many Asian countries (WHO 1997). Close to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002771-14 Sponsor Protocol Number: IC51-310 Start Date*: 2007-10-24
    Sponsor Name:Intercell AG
    Full Title: COMPARISON OF THREE COMMERCIAL BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51. DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005072-17 Sponsor Protocol Number: IC51-304 Start Date*: 2005-07-01
    Sponsor Name:Intercell AG
    Full Title: PHASE 3 STUDY TO COMPARE A RAPID IMMUNIZATION REGIME WITH THE STANDARD REGIME FOR IC51 (JE-PIV) AS VACCINE FOR JAPANESE ENCEPHALITIS
    Medical condition: Healthy volunteers: Immunization against Japanese Encephalitis virus (JEV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002894-36 Sponsor Protocol Number: IXIARO-booster-senescence Start Date*: 2017-12-22
    Sponsor Name:Medical University of Vienna (MUW)
    Full Title: "An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis...
    Medical condition: The condition under investigation is the naturally aging immune system. The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002793-64 Sponsor Protocol Number: IC51-311 Start Date*: 2007-10-24
    Sponsor Name:Intercell AG
    Full Title: EFFECT OF A BOOSTER DOSE OF THE JAPANESE ENCEPHALITIS VACCINE IC51 ON LONG TERM IMMUNOGENICITY. AN UNCONTROLLED, OPEN-LABEL PHASE 3 STUDY.
    Medical condition: Japanese Encephalitis (JE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-004181-37 Sponsor Protocol Number: B9371039 Start Date*: 2023-02-03
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
    Medical condition: Active immunization to prevent tick borne encephalitis (TBE)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000475-14 Sponsor Protocol Number: V59_38 Start Date*: 2011-10-25
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in He...
    Medical condition: Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-002076-18 Sponsor Protocol Number: IC51-309 Start Date*: 2006-07-06
    Sponsor Name:Intercell AG
    Full Title: COMPARISON OF THREE BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY.
    Medical condition: Japanese encephalitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:06:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA